BioPharmSignal logoBioPharmSignal

Biotech News

MediciNova CEO Provides Shareholder Update

MediciNova (MNOV)MediciNovaCompany update

LA JOLLA, Calif., June 30, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today provides shareholders a corporate update in the following Letter to

Related news

MNOVMediciNova2026-07-15 12:00 EST

MediciNova Announces Patient Enrollment Milestone Achieved in SEANOBI Study Expanded-Access-Program Evaluating MN‑166 (ibudilast) in ALS patients

MNOVMediciNova2026-06-08 12:00 EST

MediciNova Receives Notice of Allowance for New Patent Covering Use of MN-166 in Combination with Anti-PD-1 Immune Checkpoint Inhibitor for Glioblastoma Treatment

GANXGain Therapeutics2026-07-16 11:00 EST

Gain Therapeutics CEO Gene Mack Issues Letter to Shareholders and Provides Operational Update

View all latest news

MediciNova

MediciNova is a biotechnology company with programs in inflammation, fibrosis, and neurological disease. Its story is built around repurposing and selective development rather than broad commercial scale.

Recent company news

MNOVMediciNova2026-07-15 12:00 EST

MediciNova Announces Patient Enrollment Milestone Achieved in SEANOBI Study Expanded-Access-Program Evaluating MN‑166 (ibudilast) in ALS patients

MNOVMediciNova2026-06-30 12:00 EST

MediciNova CEO Provides Shareholder Update

MNOVMediciNova2026-06-08 12:00 EST

MediciNova Receives Notice of Allowance for New Patent Covering Use of MN-166 in Combination with Anti-PD-1 Immune Checkpoint Inhibitor for Glioblastoma Treatment

MNOVMediciNova2026-05-26 23:00 EST

MediciNova Announces Completion of Last Patient Last Visit in the MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)

MNOVMediciNova2026-04-27 23:00 EST

New Peer‑Reviewed Study Reveals Actionable Immune–Microenvironment Target in Brain Metastasis; Medicinova Advances Clinical Translation

Stock data

Close
1.36 USD
Market cap
65.96M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States